HALO (Halozyme Therapeutics) LT-Debt-to-Total-Asset: 0.72 (As of Mar. 2026)

What is Halozyme Therapeutics LT-Debt-to-Total-Asset?

Halozyme Therapeutics HALO +3.17% 92 LT-Debt-to-Total-Asset is 0.72 as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.76 (Modestly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Halozyme Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.72.

Halozyme Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.69) to Mar. 2026 (0.72). It may suggest that Halozyme Therapeutics is progressively becoming more dependent on debt to grow their business.

Halozyme Therapeutics (NAS:HALO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Halozyme Therapeutics LT-Debt-to-Total-Asset Related Terms

Halozyme Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics LT-Debt-to-Total-Asset Chart

Halozyme Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.71

0.81

0.87

0.73

0.85

Halozyme Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.69	0.74	0.36	0.85	0.72

92GF Score

Halozyme Therapeutics Inc HALO

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Halozyme Therapeutics LT-Debt-to-Total-Asset Calculation

Halozyme Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2142.63	/	2525.323
	=	0.85

Halozyme Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1935.896	/	2672.719
	=	0.72

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.72 mean?

Halozyme Therapeutics (HALO) has a LT-Debt-to-Total-Asset of 0.72 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Halozyme Therapeutics and its competitors.

Is Halozyme Therapeutics' LT-Debt-to-Total-Asset too high?

Halozyme Therapeutics' current LT-Debt-to-Total-Asset is 0.72. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Halozyme Therapeutics' LT-Debt-to-Total-Asset compare to KYMR and IBRX?

Halozyme Therapeutics' LT-Debt-to-Total-Asset of 0.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current LT-Debt-to-Total-Asset is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Halozyme Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.76, compared to a current price of $79.47 — trading 12.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.72. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current LT-Debt-to-Total-Asset is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $79.47 is trading 12.4% below its estimated GF Value™ of $90.76. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

LT-Debt-to-Total-Asset: 0.72
GF Value™: $90.76 vs. price of $79.47 (12.4% below fair value)
GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies KYMR IBRX PRAX TGTX CORT PCVX NUVL IMVT PTGX APGE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges HALO:Mexico 1HALO:Italy 0J2O:UK RV7:Germany

Address 12390 El Camino Real, San Diego, CA, USA, 92130

Website https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

92GF Score

Get the complete analysis for HALO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.47

Price

$90.76

GF Value

View HALO Analysis

See LT-Debt-to-Total-Asset data for all stocks →